Mr. Ciar?n Breen:

When we look at them as a point of risk, we look at many different issues. We do not just look at their rate of clinical negligence events on their own or their number of claims. We try to look at a more global picture of what they are doing, the number of live births and so on. More particularly, in relation to cerebral palsy, which is obviously a terrible outcome families but also in terms of its cost for the State and the system, we set up jointly with the HSE the neonatal encephalopathy group which Dr. O'Keeffe sits on with people from the HSE and other parties. The purpose of that is to examine the incidence of cerebral palsy and to try and formulate a system response, insofar as you can, to ensure that you are dealing with that issue because those events are normally not reducible to one single event. They are normally different things happening. If all these things could be looked at, then obviously you could bring down the incidence.